Safety and Efficacy of Intravenous IDOV-SAFETM in Patients With Advanced Solid Tumors

NCT06346041 · clinicaltrials.gov ↗

EARLY_PHASE1

Phase

RECRUITING

Status

19

Enrollment

OTHER

Sponsor class

Conditions

Neoplasms

Interventions

BIOLOGICAL: Oncolytic Virus injection(IDOV-SAFETM)

Sponsor

Cancer Institute and Hospital, Chinese Academy of Medical Sciences